Around 10,600 fewer breast cancer patients have started treatment in the last year in England, as experts fear hard-won progress could slow.
Hormone treatment enzalutamide will now be offered as an alternative combined treatment option for some adults with prostate cancer on the NHS in England.
Teasing apart causation from correlation is vital if we are to understand whether the gut microbiome changes the risk of cancer or whether cancer changes the gut microbiome
After a very difficult year for cancer clinical trials, we look to the future and ask what positive lessons can be learnt
We explore how our partner, Credit Suisse, adapted to significant changes in the fundraising environment to exceed its original targets for the partnership.
The Cancer Research UK Challenge Fund, which we launched in the initial throes of the pandemic, will help to ensure we can continue funding vital research.
Cancer Research UK’s spinout, Achilles Therapeutics plc (‘Achilles’), has raised $175.5 million through the closing of its initial public offering (IPO).
This year’s event took place virtually on Wednesday 12 May. Watch or listen back now.
For the first episode of our new podcast, we explore cancer and infertility.
Payam Gammage believes understanding the mutations in mtDNA could reveal indicators of cancer prognosis and a new focus for therapeutics.